Sana Biotechnology

SANA · NASDAQ

$2.36+$0.06 (+2.61%)TodayMarket closed · Oct 20, 7:44 PM ET

Prev close $2.30

SANA analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $8.60 (+264.3% upside)

Low: $6.06
Now: $2.36
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

SANA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B of A Securities	Aug 14, 2026	Maintains	Buy	$7.00 → $6.00	50%
Wedbush	Apr 14, 2026	Maintains	Outperform	$6.00 → $7.00	40%
HC Wainwright & Co.	Mar 4, 2026	Maintains	Buy	$9.00 → $7.00	27%
B of A Securities	Jan 6, 2026	Maintains	Buy	$6.00 → $7.00	—
Wedbush	Nov 7, 2025	Maintains	Outperform	$5.00 → $6.00	40%
HC Wainwright & Co.	Nov 7, 2025	Maintains	Buy	$11.00 → $9.00	27%
Citizens	Oct 30, 2025	Maintains	Market Outperform	$5.00 → $8.00	36%

The case for and against

Updated Mar 13, 2026

Bull case

Sana Biotechnology is positioned favorably within the growing biotechnology sector, as evidenced by a 32% increase in biologics usage from 2022 to 2023 in both the US and EU5, indicating a strong market demand for innovative treatment solutions. The company's development of cell therapies, particularly SG299, is expected to enhance accessibility and affordability, bolstering its market uptake beyond conventional projections for ex vivo cell therapies. Furthermore, the observation of a 40% growth in biologics usage among patients with systemic lupus erythematosus (SLE) showcases the increasing adoption of advanced therapeutic options, which could positively influence Sana Biotechnology’s market potential.

Bear case

Sana Biotechnology's stock outlook is negatively affected by concerns regarding the efficacy and safety of its lead programs, which may not yield the expected therapeutic benefits, potentially halting development or limiting market uptake. Additionally, the development of lupus nephritis (LN) is associated with severe health outcomes, including high rates of kidney failure and significant mortality risks, raising doubts about the viability of therapies in this area. Furthermore, challenges in glucose management for Type 1 diabetes patients indicate heightened morbidity risks and a decreased life expectancy, compounding the uncertainty surrounding the company's pipeline and its ability to address critical unmet medical needs effectively.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.